Moraska, A. R., Atherton, P. J., Szydlo, D. W., Barton, D. L., Stella, P. J., Rowland, K. M.,Jr, . . . Loprinzi, C. L. (2010). Gabapentin for the management of hot flashes in prostate cancer survivors: a longitudinal continuation Study-NCCTG Trial N00CB. The Journal of Supportive Oncology, 8(3), 128-132.
Examined efficacy and toxicity of gabapentin when taken for additional 8 weeks after previous study, where it was compared 3 different doses of gabapentin with placebo for treatment of hot flashes due to androgen deprivation therapy
Self completed report by participants
SITE: Mutli-site
PHASE OF CARE: Transition phase after initial treatment
APPLICATIONS: Late Effects & Survivorship; End of Life and Palliative Care
Observational, open label, and uncontrolled design continuation of randomized study
600 mg/d of gabapentin moderately decreased the hot flash score without substantial toxicities. All groups decreased hot flash scores and frequency at similar levels. Appetite loss and constipation were not increased. Troubled sleeping and nervousness scores were better in the placebo group.